Main Article Content
Serum amyloid A, serum biomarkers, lung transplantation
Background: Serum Amyloid A (SAA) is an acute phase protein overexpressed in chronic obstructive pulmonary diseases and lung cancer. In this study SAA concentrations in patients undergoing lung transplantation (LTX) were firstly performed to assess its potential value as biomarker of LTX complications.
Methods: We enrolled 26 patients undergoing LTX (13 males, 58.6 ± 11 years) and 11 healthy controls (3 males, 55 ± 11.3 years). LTX patients were subdivided in three groups: acute rejection (AR) (7 patients), chronic lung allograft rejection (CLAD) (3 patients), acute infection (INF) (9 patients) and stable patients (NEG) (7 patients), according to transbronchial evaluation.
Results: In LTX patients, SAA concentrations were significantly increased compared to healthy controls (p <0.05), particularly in patients with AR and INF (p < 0.05). In LTX patients with AR were observed a correlation between SAA levels and peripheral CD4+ lymphocyte percentage (r=0.9, p<0.01) and a reverse correlation with FVC percentages (r -0.94, p = 0.01). Outcome analysis showed a trend between SAA concentrations and mortality.
Conclusions: Acute phase protein SAA may represent a potential biomarker of LTX acute complications. Its correlations with functional and immunological bioindicators suggest a promising prognostic value in AR.